Provider of sea transportation service for passengers and freight. The company provides regular services between the Continent and Corsica and international lines to Sardinia, Tunisia, and Algeria. The company also offers products and services linked to its core activity, including freight, international transit, travel agency, business tourism, and consignment shipping.
Missing: SNCM's Product Demo & Case Studies
Promote your product offering to tech buyers.
Missing: SNCM's Product & Differentiators
Latest SNCM News
Nov 21, 2022
Coronary stents likely to become more affordable, NPPA to decide price Coronary stents likely to become more affordable, NPPA to decide price The move is based on the recommendations by an expert committee constituted to review the inclusion of stents in the list based on requirement. "As far as medicines are concerned, SNCM has already submitted its report on NLEM, 2022 and the same has been adopted by the government," an official source said. Updated Nov 21, 2022, 10:00 AM IST The Union health ministry has notified the inclusion of coronary stents in the National List of Essential Medicines, 2022, a move that will help make these life-saving medical devices more affordable. The move is based on the recommendations of an expert committee constituted to review the inclusion of stents in the list based on requirements. The National Pharmaceutical Pricing Authority (NPPA) will now fix the price of coronary stents. On November 6, the Standing National Committee on Medicines (SNCM) submitted its recommendation for the inclusion of coronary stents in the National List of Essential Medicines (NLEM), 2022 in two categories -- Bare Metal Stents (BMS) and Drug Eluting Stents (DES) which include metallic DES and bioresorbable vascular scaffold (VBS)/biodegradable stents. According to minutes of the SNCM meeting, vice chairman Dr. Y K Gupta stated that coronary stents were earlier included in NLEM, 2015 through a separate notification based on the recommendations of an expert committee. "As far as medicines are concerned, SNCM has already submitted its report on NLEM, 2022 and the same has been adopted by the government," an official source said. The SNCM deliberated on the essentiality, categorisation, and other relevant aspects of coronary stents. It also stated that coronary artery diseases (CAD) is a public health issue that is associated with high morbidity and mortality. There is an enormous need for percutaneous coronary interventions requiring the implantation of coronary stents. Therefore, coronary stents should continue to be essential medical devices, committee members agreed. "After taking into consideration all aspects of coronary stents, the committee recommended that coronary stent is an essential medical device which has been notified as a 'drug' under the Drugs and Cosmetics Act, 1940 and therefore, it should be included in NLEM, 2022," an official said. Authorities for the purpose of NLEM in respect of coronary stents should consider various coronary stents separately under the categories of Bare Metal Stents and Drug Eluting Stents, he said. The Indian Council of Medical Research and other relevant institutions may also consider taking necessary initiatives to generate data for assessment of post-marketing safety and performance of coronary stents being used in various hospitals/institutions, the members stated. "Following the recommendations by the expert committee, the Union health ministry has notified the inclusion of coronary stents in the National List of Essential Medicines (NLEM), 2022," the official added. Several anti-cancer drugs, antibiotics, and vaccines were among 34 new additions to the National List of Essential Medicines released on September 13, taking the total number of drugs under it to 384. TAGS:
SNCM Frequently Asked Questions (FAQ)
Where is SNCM's headquarters?
SNCM's headquarters is located at 61 Boulevard des Dames, Marseille.
What is SNCM's latest funding round?
SNCM's latest funding round is Secondary Market.
Who are the investors of SNCM?
Investors of SNCM include Butler Capital Partners.